share_log

Morgan Stanley Initiates Coverage On Senti Biosciences With Equal-Weight Rating, Announces Price Target of $7.5

Morgan Stanley Initiates Coverage On Senti Biosciences With Equal-Weight Rating, Announces Price Target of $7.5

摩根士丹利以同等权重评级启动对Senti Biosciences的报道,宣布目标股价为7.5美元
Benzinga Real-time News ·  2022/10/07 06:12

Morgan Stanley analyst Michael Ulz initiates coverage on Senti Biosciences (NASDAQ:SNTI) with a Equal-Weight rating and announces Price Target of $7.5.

摩根士丹利分析师迈克尔·乌尔兹以等权重评级开始对Senti Biosciences(纳斯达克股票代码:SNTI)进行报道,并宣布目标股价为7.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发